CAS has migrated to this web app on 5/23/21. If you have an active membership on 5/23/21, log in with your email and password. Otherwise, please create a new account.
Antibody-drug conjugate (ADC) leverages the benefits of the high specificity from monoclonal antibody drugs and the high potency from small-molecule drugs to improve efficiency with reduced side-effects. Up to date, 11 ADC drugs have been approved by US FDA for marketing; 90 ADC drugs are in the clinical stage; and more than 200 are under discovery and preclinical development. Although ADC drugs have achieved impressive clinical outcome, there are still many challenges to overcome, such as toxic side effects, lack of biomarkers for screening patients, and development of drug resistance. Discovery of novel targets, conjugation technologies, and new payload modalities opens a new era of ADC therapeutics development.
Chinese Antibody Society (CAS) is pleased to continue hosting mAbTalks series in 2021 - “New Horizon of Antibody-Drug Conjugate (ADC)” virtual symposium. The symposium will be held online via Zoom and free for registration. In our half-day event, speakers from both industry and academia will share their insights in diverse topics of ADC-based therapeutics, including discovery & new techniques, clinical development strategies, and CMC. Dr. Daotian Fu, President of RemeGen, Co., Ltd., and a board member of CAS, will be the symposium chair. This event is a perfect opportunity for the attendees to stay up to date on the most recent progress and challenges in ADC-based drug development. We have invited distinguished guest speakers in biopharma industry and academia specializing in ADC-based drug development. Online LIVE Q & A sessions will be included after every presentation. We sincerely invite you to join us online on May 22, 2021 evening (US EST)/May 23, 2021 morning (Beijing Time), enjoying the cutting-edge science and direct communications with ADC experts in the field.
Coincident with this ADC symposium, CAS’ official journal, Antibody Therapeuticspublished by Oxford University Press is organizing a special issue with focus upon “Antibody-targeted Cytotoxic agents – Immunotoxins and ADCs”. You are welcome to click here if you’d like to make contribution.
Hover above speaker cards to read bio
Daotian Fu, PhD
Christoph Rader, PhD
Associate Dean, The Scripps Research Institute
Xinfang Li, PhD
Kyoji Tsuchikama, PhD
Assistant Professor, The University of Texas Health Science Center at Houston
Yongxin Zhao, PhD
President, DAC Biotech
Shan Jiang, PhD
Executive Director, Pharmaceutical Sciences, Seagen Inc.
Jacqueline Ming Liu, MD
Chief Medical Officer, TOT Biopharm
Starts at 05/22/2021 8 p.m. (US EDT) | 05/23/2021 8 a.m. (Beijing)
Hover to view abstract
05/22/2021 8 p.m. EDT
Introduction to Chinese Antibody Society and mAbTalk
Daotian Fu, PhD, President, RemeGen
05/22/2021 8:10 p.m. EDT
Next-Generation Antibody-Drug Conjugates
Christoph Rader, PhD, Associate Dean, The Scripps Research Institute
05/22/2021 8:40 p.m. EDT
A novel ADC platform and the ADCs generated from the platform in the targeted treatment of cancer
Yongxin Zhao, PhD, President, DAC Biotech
05/22/2021 9:10 p.m. EDT
Novel Linker Technologies for Generating ADCs for Cancer Therapy
Kyoji Tsuchikama, PhD, Assistant Professor, The University of Texas Health Science Center at Houston
05/22/2021 9:40 p.m. EDT
Organizer, , The Chinese Antibody Society
05/22/2021 10:10 p.m. EDT
Advancing ADCs for Transformative Cancer Therapies
Shan Jiang, PhD, Executive Director, Pharmaceutical Sciences, Seagen Inc.
05/22/2021 10:40 p.m. EDT
Challenges in the Clinical Development of Antibody Drug Conjugates
Jacqueline Ming Liu, MD, Chief Medical Officer, TOT Biopharm
05/22/2021 11:10 p.m. EDT
ADC Product Quality Development and Control
Xinfang Li, PhD, President, MabPlex